Evaluation of the Efficacy of Coriolus versicolor* in the Treatment of HPV Lesions (LSIL).

Evaluation of the Efficacy of Coriolus versicolor* in the Treatment of HPV Lesions (LSIL). J. Silva Couto¹ , L. Salgueiro² – Jsilvacouto@netcabo.pt

This poster was presented at the 14th World Congress of Cervical Pathology and Coloscopy, July 4-7, 2011 in Rio de Janeiro, Brasil
Conclusion: The use of Coriolus versicolor for one year revealed a great efficacy, whether in the regression of the displasia (LSIL) or in the disappearance of the High Risk HPV. It seems therefore, to be a very useful food supplementation with positive therapeutic impact, either in the reversion of LSIL (with High Risk HPV+), or in those HSIL patients, who have undergone surgery but experience continued High Risk HPV viral count.

¹ Gynaecology Department-Portuguese Institute of Oncology-Cervical Pathology Unit, Coimbra, Portugal
² CEF/Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Early Phase II RCT of Tramates (Coriolus) versicolor (1500 mg TID PO) in Women with Stage (I/II/III) ER/PR Negative Breast Cancer

The main outcome was to study the mean rate of change in Natural Killer Cell Activity in patients who have undergone conventional breast câncer protocol: chemotherapy followed by radiotherapy in which there is a subseqent decrease in Natural Killer Cell Activity. The study was funded by CTRF and was halted as naturopaths were unable to recruit patients for the study. The attachments outline the rational for the study along with timeline.

Download the CTRF Clinical Study, click here.
Download the CTRF Clinical Timeline, click here.

Coriolus versicolor supplementation in HPV patients

Dr. Jose Silva Couto and Dr. Daniel Pereira da Silva of the Cervical Pathology Unit of the Portuguese Institute of Oncology in Coimbra, Portugal
March 7th, at the 20th European Congress of Obstetrics and Gynaecology
This poster presents the results of a year long study on Coriolus versicolor supplementation in HPV patients with low-grade squamous intraepthithelial lesions (LSIL).
Download also the pressrelease, click here.

“Cancer Prevention with Supplementation of Diets with Botanicals”

by Karmali, A. and Fernandes, T.H.
ESCVN/ ECVCN – 5 – 7th October 2006 - Nantes
This work was conducted with a mushroom (Coriolus versicolor) which is in the market for human and animal use. Mushroom polysaccharides, particularly ß-glucans, have antitumour and immunomodulating properties.

“Coriolus”

by Dr. Jean Monro, Breakspear Hospital, Hempel Hemstead-Tel:44-1442-261-333. (www.breakspearmedical.com)
Journal of Integrative Medicine 2004;8:101-108
In this article Dr. Jean Monro of Breakspear Hospital, has demonstrated in a group of 36 patients who have had defined chronic fatigue syndrome and autonomic dysfunction that Coriolus MRL has been an immuno-therapeutic agent. It has improved natural killer cells numbers by 35% in this group with a two months course of treatment.

"Treatment of Cancer with Mushroom Products"

by Dr. Jean Monro, Breakspear Hospital, Hempel Hempstead-Tel:44-1442-261-333.
Archives of Environmental Health, August 2003 (Vol. 58 (No.8 )). Reprinted with permission of the Helen Dwight Reid Educational Foundation. Published by Heldref Publications, 1319 18th Street, NW, Washington, DC 20036-1802. Copyright © (2004).
In this article Dr. Monro points discusses how 20% of all cancers are triggered by viral infections. Dr. Monro outlines that having provided 30 Chronic Fatigue Syndrome patients Coriolus-MRL supplementation over eight weeks, there were significant improvements in the overall immune systems of the majority of the patients and that Coriolus supplementation could be utilized as a preventative immunutrition for those patients with such viral conditions that could develop into more serious oncological conditions i.e. HPV infection or Epstein Barr infection. Dr. Monro also outlines that Coriolus supplementation not only increases Natural Killer cell activity by 35%, but may also play a role in facilitating intercellular communication, thereby allowing the immune system to operate more effectively.

For more information on Heldref Publications and the Archives of Environmental Health, see the following links:
http://www.heldref.org and http://www.heldref.org/aeh.php.

"The Use of Ganoderma lucidum (Reishi) in the Management of Histamine-Mediated Allergic Responses"

by Martin Powell (BSc.Hons., Dip.Ac, Dip.CHM, MRCHM - Natural Health Centre, Luton, United Kingdom Tel:44-1582-418-886).
Published October 2004 in Nutritional Practitioner Magazine (ISSN 1472-0094).
Allergies and asthma are two examples of histamine-mediated allergic responses. Both conditions are increasing in frequency and are difficult to target with modern medicine. The modern approach to drug research is target specific and does not consider the natural defense mechanisms of the body or the causative factors (a cytokine TH1 to cytokine TH2 shift) underlying histamine-mediated allergic responses. Ganoderma lucidum (Reishi) as immunonutrition, with its unique array of compounds working in concert, could play a major role in treatment of histamine-mediated allergic responses.

"The Effectiveness of Coriolus versicolor in the Treatment of Secondary Phenomena Associated with HIV"
by Dr. Grazia Rotolo, Piazza San Theodoro, 27100, Pavia, Italy
Presented at the 10th International Congress of Mucosal Immunology in Amsterdam, June 28th - July 1st, 1999.
This curiosity outlines the impact of Coriolus versicolor supplementation on the White Blood Count (WBC) in three HIV positive patients at the following intervals of supplementation: Days 1-15 at 3.0 grams per day; Days 16-45 at 1.5 grams per day. Results: a 45% increase in WBC over 45 days.
To Contact Dr. Grazia Rotolo, please contact grotolo@venus.it

"The Effectiveness of Coriolus versicolor Supplementation in the Treatment of Kaposi sarcoma in HIV+Patients"
by John Tindall and Elizabeth Clegg, Gateway Clinic, Community Health, South London, NHS Trust 108, Landor Road, London SW9 9NT England
Presented at the 10th International Congress of Mucosal Immunology in Amsterdam, June 28th - July 1st, 1999.
This curiosity outlines the impact of Coriolus supplementation (6.0 grams per day to 9.0 grams per day) on the CD4 levels and viral load levels of three (3) Kaposi sarcoma patients. Results: For Kaposi sarcoma patients, Coriolus versicolor supplementation at 6.0 grams per day to 9.0 grams per day can significantly increase CD4 levels and provide a better quality of life.
To Contact Mr John Tindall please contact Yuan Clinic at:
Yuan Clinic
c/o Green Healer
7 Clapham High Street
London SW4 7TS
United Kingdom
Tel/Fax:+44-207-622-9079.

"The Clinical Use of Coriolus versicolor Supplementation in HIV+ patients and the Impact on CD4 Count and Viral Load"

by Marijke Pfeiffer-Centrum Voor Integrale Geneeskunde, Amsterdam.
Presented at the III International Symposium on Mushroom Nutrition in Milan on Saturday, March 10th, 2001.
This case study outlines the changes in CD4 levels and viral loads of eight (8) HIV+ patients on Coriolus versicolor supplementation levels of 1.5 grams per day over a twelve (12) month period. Results: Coriolus versicolor supplementation as low as 1.5 grams per day can increase CD4 levels and decrease viral loads in HIV+ patients. For similar impact in post-HAART patients the supplementation levels must be at 3.0 grams per day.
To contact Ms. Marijke Pfeiffer
Centrum Voor Integrale Geneeskundes
Amsterdam, The Netherlands
Fax:31-20-624-9710
Email: cig@xs4all.nl

"Pioneering Work at Breakspear Hospital on Coriolus Suplementation for CFIDS/ME Patients"

by Dr. Jean Monro, Breakspear Hospital.
In this case study on the use of Coriolus versicolor in fifteen (15) patients with Chronic Fatigue Syndrome, Dr. Monro measures the increase in Natural Killer Cell (NK) activity over forty five days when Coriolus supplementation is given at 3.0 grams for fifteen (15) days and then decreased to 1.5 grams for thirty (30) days. Results: Coriolus supplementation increased NK cell activity significantly in Chronic Fatigue Syndrome patients.
To contact Dr.Jean Monro at Breakspear Hospital
Tel:44-1442-261-333 / Fax:44-1442-266-388

"Cytokine Th1 to Th2 Shift Can be Reversed by Coriolus versicolor Supplementation. Prospective Trial for HPV Control with Coriolus versicolor"

By Dr. Jean Monro, Breakspear Hospital.
Presented at the 2nd International Symposium on HPV and Cancer, in Lisbon Portugal on May 26th, 2001.
This prospective trial design outlines the rational for the use of Coriolus versicolor supplementation (3.0 grams per day) to improve the immune system in HPV infected women in order to control the stage of HPV development. Dr. Monro is the first to suggest that Coriolus versicolor supplementation may reverse a Th1 to Th2 shift in the immune system.
To contact Dr.Jean Monro at Breakspear Hospital
Tel:44-1442-261-333 / Fax:44-1442-266-388

“The Role of Mushroom Nutrition as A Delivery Agent for Enzyme Therapy in Cancer Care?”
by Professor Amin Karmali - Biotechnology Section, Instituto Superior de Engenharia de Lisboa (ISEL).
Presented at the 4th International Symposium on Mushroom Nutrition, University of Westminster, June 15th, 2002.
In this abstract, Professor Karmali examines the in vitro content of lacasse activity, protease activity, peroxidase activity and glycomylase activity (glycose-2-oxidase) of various mushrooms (Grifola frondosa, Ganoderma lucidium, Cordyceps sinensis and Coriolus versicolor ) per 500 mg tablet.
To contact Professor Karmali Biotechnology Section
Instituto Superior de Engenharia de Lisboa (ISEL)
Tel:351-21-831-7052 / Fax:351-21-831-7267 Email: akarmali@isel.ipl.pt

"Pilot Study to Investigate the Changes in Metabolic and Physiological Parameters using Cordycpes sinensis supplementation (3.0 grams per day ) in a double blind, randomized format in 18 Healthy Volunteers."
By Professor Paul Leonard Greenhaff (Ph. D), Queen´s Medical School, University of Nottingham.
The objective of this study is to confirm that heathy subjects will not be adversely impacted by Cordyceps sinensis supplementation (3.0 grams per day) over 4 weeks.

"Double Blind Placebo Controlled Perspective Trial to Investigate the Effect of Cordyceps sinensis Supplementation in Minimizing Anxiety, Depression and Fatigue Associated with Chronic Hepatitis C."
Trial designed by Professor Robert Batey, Dr.Ian Murray and Dr. Graham Foster
Poster Presentation at the 6th International Mainliner Hepatitis C Conference in Lisbon, Portugal, February 7th-8th, 2002.
Mycology Research Laboratories is seeking funds to complete this study in 2004.

"Chronic Fatigue Syndrome and Breast Lumps/ Myomas:the Liver Link, a TCM Perspective"
by Professor Nuria Lorite Ayan (Lic. TCM, Ac., Homeopath and Pharmacist).
Presented at the 4th International Symposium on Mushroom Nutrition, University of Westminster, June 15th, 2002.
Professor Lorite gives a Traditional Chinese Medicine (TCM) perspective on the reason that women having Chronic Fatigue Syndrome over a long period of time may suffer from breast lumps / myomas. She provides suggestions for treatment from a TCM perspective that includes acupuncture, herbs and Coriolus versicolor supplementation.
To contact Professor Nuria Lorite
Centro Biloba
C/ Del Rey 6 bajo
28200 San Lorenzo de El Escorial
Madrid, Spain
Tel:34-91-890-00-85
Email: nuria.lorite@eagora.info

"The Use of Coriolus versicolor Supplementation in Breast Cancer Patients - Case Study"
by Dra. Ana Ferro / Paula Boaventura
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
This abstract outlines the impact of using 4.5 grams per day of Coriolus versicolor supplementation in a breast cancer patient undergoing chemotherapy. The case study outlines the significant impact of Coriolus supplementation on immune parameters and on the quality of life for the patient.
To contact Dra. Ana Ferro / Paula Boaventura
Clinica de Saúde Integral
Rua Constitução, 1959-loja A 4250 / 170 Porto, Portugal
Fax:351-22-832-80-49 / Tel:351-22-832-80-47

"Observational Non-Controlled Study of the Use of Coriolus versicolor Supplementation in 30 Cancer Patients"

by Dr. Julian Kenyon
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
This study of increasing Coriolus versicolor supplementation (4.5 grams per day to 13.0 grams per day over a 90 day period) measures the impact of such supplementation on telomerase activity, interleukin 5, interleukin 12 and Tumour Necrosis Factor Beta over 120 days. Results were a significant decrease in teleomerase and interleukin-12 activity, followed by a significant increase in interleukin-5 activity within 120 days.
To contact Dr. Julian Kenyon (MD MB ChB)
Dove Clinic for Integrated Medicine
97 Harley Street
London W1G 6AG
United Kingdom
Tel:44-207-487-4442
Email: doveclinic@ukonline.co.uk
http://www.doveclinic.com

"Super-Oxide Dismutase (SOD), Cytochrome P-450, Cytochrome P-450 reductase and secondary metabolites - Chemical and Biological Properties in Mushroom Nutrition" by Professor Amin Karmali
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
In this abstract, Professor Karmali measures the in vitro content of SOD, Cytochrome P-450, Cytochrome P-450 reductase in various mushrooms (Grifola frondosa, Ganoderma lucidium, Cordyceps sinensis and Coriolus versicolor) per 500 mg tablet.
To contact Professor Karmali Biotechnology Section
Instituto Superior de Engenharia de Lisboa (ISEL)
Tel:351-21-831-7052 / Fax:351-21-831-7267
Email: akarmali@isel.ipl.pt

"The Effect of Aqueous Extracts of MRL Products on Viability of HepG2 Liver Cancer Cells" by Dr. Chris Newton (Ph.d) Cytogenex
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
A request was made to CytoGenex to determine whether the MRL nutritional support products, known as Coriolus (BN 03143), Reishi (BN 02194), Cordyceps (BN 03021) and Maitake (BN 03165) had any significant toxicity when tested with a standard toxicity screen. A system has been developed by Cytogenex laboratories based on the liver cell line, HepG2. Toxicity has a number of connotations, but Cytogenex Laboratories takes the term to mean that the test article causes 'no apparent loss of viability of cells used as an assay system'. Viability in this context is taken to mean that cell integrity is maintained. Loss of viability for a cell population is equated with the occurrence of cell death by the mechanism of apoptosis or necrosis. This presentation presents the results of this analysis.
To contact Dr. Chris Newton
CytoGenex Ltd.
121 Westbourne Avenue
Kingson-upon Hull
HU5 3HU
Tel:44-1482-346-381
http://www.cytogenex.com